Popular

Tesamorelin – 10mg

10mg

$88.99

10 in stock

Bulk Pricing – Save More

Buy 3 units 5% OFF

$84.54 each Total: $253.62 (Save $13.35)

Buy 5 units 10% OFF

$80.09 each Total: $400.46 (Save $44.50)

Buy 10 units 15% OFF

$75.64 each Total: $756.42 (Save $133.49)

Clear selection

Overview

Tesamorelin 10 mg is a stabilized synthetic peptide. It is an analog of growth hormone–releasing hormone (GHRH 1–44). The peptide includes an N-terminal trans-3-hexenoic acid modification. This change improves stability and limits enzymatic degradation. Tesamorelin is a 44–amino acid polypeptide. It binds to GHRH receptors on pituitary somatotroph cell, and this binding stimulates endogenous growth hormone synthesis. It also promotes pulsatile GH secretion in research models. The peptide is supplied as lyophilized powder. Purity is at least 99 percent by HPLC analysis. Each vial contains 10 mg for laboratory research use. Researchers use tesamorelin to study the somatotropic axis. Common areas include endocrine signaling and metabolic regulation. It also supports research on fat distribution and GH–IGF-1 pathways. Tesamorelin is intended only for in vitro and in vivo research. It is not approved for human consumption or therapeutic use.

Tesamorelin Mechanism of Action in Research Models

In preclinical and investigational studies, tesamorelin acts as a selective GHRH receptor agonist. It binds to the growth hormone–releasing hormone receptors on pituitary cells. This binding activates Gs-protein signaling pathways. Activation increases intracellular cyclic AMP levels. It also raises protein kinase A activity. These signals promote transcription of growth hormone genes. The result is enhanced pulsatile GH release. Growth hormone stimulates hepatic IGF-1 production. IGF-1 promotes lipolysis in research models. It also limits adipocyte differentiation. These effects favor fat mobilization, especially in visceral tissue. The trans-3-hexenoic acid modification improves resistance to DPP-IV cleavage. This change extends peptide stability. It also supports a more favorable pharmacokinetic profile than native GHRH.

Tesamorelin Peptide Sequence

Tesamorelin is a linear peptide with 44 amino acids. It includes an N-terminal trans-3-hexenoyl modification.

Peptide sequence:

trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂

Chemical details include:

Molecular formula: C₂₂₁H₃₆₆N₇₂O₆₇S

Molecular weight: approximately 5135.78–5136 Da

Key modification: N-terminal trans-3-hexenoyl group

CAS number: 218949-78-1

This structure preserves full GHRH bioactivity. It also extends the half-life in experimental systems.

Tesamorelin Research

Tesamorelin has been widely studied in metabolic research. Early work focused on HIV-associated lipodystrophy, and researchers also examined visceral adiposity and endocrine dysfunction. VAT reduction is reported under randomized controlled trials. Over 26 weeks, the average reduction reached 15 to 18 percent, and the placebo groups also showed increases in visceral fat. Extended studies reported sustained effects up to 52 weeks. Research also showed reductions in liver fat content. Some cohorts reported decreases of nearly 80 percent. Improvements appeared in lipid profiles and insulin sensitivity markers. Aminotransferase levels also improved in subjects with elevated baselines. Additional studies explore NAFLD and obesity-related insulin resistance. Tesamorelin increases IGF-1 levels in a dose-dependent manner. Pulsatile GH patterns remain intact. This differs from continuous GH infusion models. Safety data report mostly mild injection-site reactions. Transient IGF-1 elevations require monitoring. No clear liver injury appeared in trials, and the ongoing research examines long-term endocrine effects and receptor kinetics.

How to Store and Handle Tesamorelin

Tesamorelin is supplied as a lyophilized powder. Store unopened vials at 2 to 8 degrees Celsius. Protect the product from light and moisture. Do not freeze the powder. Reconstitute using bacteriostatic water or sterile diluent. Perform all steps under aseptic conditions, and refrigerate reconstituted solutions after mixing. Use solutions within established stability periods. Follow protocol-specific guidelines. Always use sterile tools and proper protective equipment.

Disclaimer

Tesamorelin is an investigational research peptide. It is intended only for laboratory and animal research. It is not approved for general human use. Regulatory approval exists only for specific prescription products. Research-grade tesamorelin is not approved for therapy or supplementation. It falls under research chemical classifications, including WADA S0. Preclinical findings do not predict outcomes outside studied settings. No claims are made regarding safety or effectiveness in humans. Handle only in qualified research facilities with institutional oversight. Products are sold strictly for laboratory use only.

Referenced Citations

Falutz J, et al. (2010). Metabolic effects of a growth hormone-releasing factor in patients with HIV. Annals of Internal Medicine. 152(5):323–331.
Gelato MC, et al. (2005). Effects of tesamorelin in HIV-infected patients with excess abdominal fat. Journal of Clinical Endocrinology & Metabolism. 90(9):5247–5253.
Stanley TL, et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA. (Related data from the NATAP source).
NCBI LiverTox: Tesamorelin – Mechanism, clinical use in HIV lipodystrophy, and safety profile (NBK548730).
Additional insights from supplier data: Purity ≥99%, lyophilized form, research-only use.

Research Use Only

This product is intended for laboratory research use only. It is not intended for human or animal consumption, or for use in diagnostic or therapeutic procedures.

Chemical Properties

Property	Value
Molecular Formula	C221H366N72O67S
Molecular Mass	5136 g/mol
Monoisotopic Mass	5132.7166406 Da
Polar Area	2360 Å²
Complexity	12800
XLogP	-23.3
Heavy Atom Count	83
Hydrogen Bond Donors	8
Hydrogen Bond Acceptors	76
Rotatable Bonds	187
PubChem CID	16137828
InChI	InChI=1S/C221H366N72O67S/c1-25-28-30-53-163(308)260-145(92-120-54-58-122(299)59-55-120)198(343)255-116(21)…(truncated for brevity)
InChIKey	QBEPNUQJQWDYKU-BMGKTWPMSA-N
IUPAC Name	(4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[…]]
SMILES	CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)…(truncated for brevity)

Certificate of Analysis

Quality

Every batch of Tesamorelin – 10mg is tested for purity and identity using industry-standard methods.

HPLC Analysis

High-Performance Liquid Chromatography confirms purity ≥98%. Each batch is analyzed to ensure consistent quality.

Mass Spectrometry (MS)

Identity verification via mass spectrometry confirms correct molecular weight of 4113.58 g/mol.

Third-Party Testing

All products undergo independent third-party laboratory testing for quality assurance.

Request COA

Certificate of Analysis documents are available for all products. Contact us with your order number to request batch-specific documentation.

COA Lab Tests

Each product batch is tested by independent laboratories to verify purity, identity, and quality. The Certificate of Analysis (COA) provides transparent lab results, ensuring the product meets strict research-grade standards.